VCP
GILD icon

Verus Capital Partners’s Gilead Sciences GILD Stock Holding History

Verus Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
3,112
+230
+8% +$30.3K 0.02% 337
2026
Q1 		$402K Sell
2,882
-147
-5% -$20.6K 0.03% 311
2025
Q4 		$372K Buy
+3,029
New +$368K 0.02% 317
2023
Q1 		– Sell
-2,747
Closed -$236K – 300
2022
Q4 		$236K Buy
+2,747
New +$218K 0.04% 230
2020
Q1 		$498K Buy
6,655
+3,168
+91% +$219K 0.16% 92
2019
Q4 		$227K Buy
+3,487
New +$227K 0.07% 215

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verus Capital Partners's GILD Position: Q2 2026 in Review

Verus Capital Partners increased its Gilead Sciences (GILD) stake by 8% in Q2 2026, buying an estimated $30.3K and bringing the position to 3,112 shares worth $393K. The position accounts for 0.02% of the portfolio, ranked #337.

Verus Capital Partners first reported a position in GILD in Q4 2019 and has held it in 6 quarters since. The position peaked at $498K in Q1 2020. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Verus Capital Partners held 3,112 shares of Gilead Sciences worth $393K as of Q2 2026.
  • Verus Capital Partners bought 230 Gilead Sciences shares in Q2 2026, an estimated $30.3K.
  • Gilead Sciences made up 0.02% of Verus Capital Partners's portfolio in Q2 2026, its #337 holding.
  • Verus Capital Partners first reported a position in Gilead Sciences in Q4 2019 and has held it in 6 quarters since.
  • Verus Capital Partners's Gilead Sciences position peaked at $498K in Q1 2020.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.